Zydus Lifesciences's Typhoid Vi conjugate vaccine, ZyVac TCV, has received WHO prequalification, making it eligible for UN ...

Zydus Lifesciences' ZyVac TCV receives WHO prequalification, eligible for U.N. procurement, combating typhoid fever in ...

Indian multinational pharmaceutical company Zydus Lifesciences Ltd on Wednesday announced that its Typhoid Vi conjugate ...

ZyVac TCV is designed for active immunization against Salmonella typhi infection in individuals aged 6 months to 65 years.

Zydus Lifesciences' shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, ...

Zydus Lifesciences' ZyVac TCV typhoid vaccine receives WHO prequalification, opening doors for UN procurement programs in ...

Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health ...

Zydus Lifesciences advanced 1.71% to Rs 1,005.05 after the company received in principle acceptability from World Health Organisation (WHO) for its ZyVac TCV vaccine.

As per GAVI (2022) it is estimated that Typhoid accounts for an estimated 11 to 21 million cases of febrile illness and ...

ICMR partners with Zydus Lifesciences for Desidustat phase-2 trials in sickle cell disease patients, aiming for innovative ...

Zydus Lifesciences Ltd has received approval from the WHO for its Typhoid conjugate vaccine, ZyVac TCV, to be procured by United Nations agencies. Developed in Ahmedabad, it targets ages 6 months to ...

Zydus Lifesciences shares were trading flat on October 18 after the company received final approval to manufacture ...